How Nurr1 interacts with Parkinson's risk factors and how drugs or natural molecules might control it

Who could benefit from this research

What this research studies

Researchers will test how the Nurr1 protein interacts with known Parkinson's risk factors, including α-synuclein and toxin models, using lab-grown neurons and animal models. They will examine synthetic drugs (such as amodiaquine) and natural molecules (such as prostaglandins) that bind Nurr1 to see whether they restore its function and reduce neuron damage. The team will use viral tools and known toxins to mimic Parkinson's changes and measure neuron survival, inflammation, and α-synuclein aggregation. Results will guide whether boosting Nurr1 is a promising path toward future therapies.

Why it matters

Where this research is happening

• Mclean Hospital
  Belmont, United States Active

Researchers

• Principal investigator: Kim, Kwang-Soo — Mclean Hospital
• Study coordinator: Kim, Kwang-Soo

Related research

Other NIH-funded projects on the same topics.

• Markers and risk factors for early (prodromal) Parkinson's and how it progresses

  This project follows people with early signs of Parkinson's to find markers that predict who will go on to develop Parkinson's and how symptoms change over time.

  NIH research Harvard University D/b/a Harvard School of Public Health · Boston, United States · NIH-11317223

• Investigating how Nurr1 interacts with Parkinson's disease risk factors and its regulation by specific compounds.

  This study is looking at a protein called Nurr1 to see how it affects the brain cells that produce dopamine in people with Parkinson's disease, and it hopes to find new ways to help slow down the disease by testing different natural and synthetic compounds that can boost Nurr1's activity.

  NIH research Mclean Hospital · Belmont, United States · NIH-11086085

• Investigating early signs and risk factors for Parkinson's disease

  This study is looking at the early signs of Parkinson's disease to help understand how it develops, and it's for people who might be experiencing these early symptoms; participants will take some tests and surveys to help researchers find ways to prevent the disease in the future.

  NIH research Harvard School of Public Health · Boston, United States · NIH-11059852

• Gut-brain clues in Parkinson’s disease: supplement to a large registry

  A plant-wide supplement to an NIH program will enroll people with Parkinson’s, with and without GI symptoms, plus healthy controls, to study how gut function, brain signals, and sleep rhythms relate to Parkinson’s symptoms.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11612995

• P-CARRS-BRAIN: Predicting Alzheimer’s risk in South Asians in India using genetic, behavior, and vascular data

  Aims to predict Alzheimer’s disease risk in middle-aged South Asians by combining genetic, lifestyle, and vascular information to catch early changes before dementia develops.

  NIH research Emory University · Atlanta, United States · NIH-11604418

• P-CARRS-BRAIN: Predicting Alzheimer’s risk in South Asians in India using genetics, behavior, and vascular data

  Aimed at people 21 and older, this project looks at how biology, behavior, and blood vessel health together may signal the early risk of Alzheimer’s disease and related dementias in South Asians.

  NIH research Emory University · Atlanta, United States · NIH-11604417

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.